#AbbVie's long-acting anti-IL-13 antibody #zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – has hit the mark in a phase 2b trial in #atopicdermatitis, its lead indication.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#AbbVie's long-acting anti-IL-13 antibody #zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – has hit the mark in a phase 2b trial in #atopicdermatitis, its lead indication.
@newsen.bsky.socialAbbVie Presents Promising Phase 2 Results for Zumilokibart at EADV 2026 as a Late Breaker #United_States #AbbVie #North_Chicago #Zumilokibart #EADV